文献速递其他结缔组织病

特发性炎症性肌病的HLA变异分析与自身抗原表位预测

HLA variation analysis and autoantigen epitope prediction in idiopathic inflammatory myopathies.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该观察性病例对照研究纳入147例活检确诊的特发性炎症性肌病(IIM)患者和114例民族匹配的健康对照,进行高分辨率HLA基因分型,比较等位基因和氨基酸频率,并用计算机工具预测关键HLA相关自身抗体亚组的表位。研究发现HLA-C*07:01对IIM具有保护作用,HLA-A*33:03与皮肌炎(DM)及抗Mi2亚组强相关,DQB1*06:03与多发性肌炎(PM)相关,抗Ro52与B*08:01相关,并预测出三个与A*33:03稳定结合且无变应原性和毒性的Mi-2肽段。

要点

  • HLA-C*07:01对IIM具有保护作用(OR=0.17)。
  • HLA-A*33:03与DM及抗Mi2亚组强相关,DQB1*06:03与PM相关。
  • 预测出三个与A*33:03稳定结合的Mi-2肽段,无变应原性和毒性。

核心结论

  • 在抗Mi2亚组中识别出新的HLA等位基因、氨基酸变异和免疫原性表位,支持HLA限制性抗原呈递在疾病发病机制中的作用,并提示抗原特异性免疫治疗的候选靶点。
  • 抗Mi2相关的HLA/表位发现因统计功效有限属于探索性,需在更大队列中确认并实验验证。

研究设计与样本

  • 观察性病例对照研究,纳入147例活检确诊的IIM患者和114例民族匹配的健康对照。
  • 患者按临床和自身抗体定义分为亚组,进行高分辨率HLA基因分型,比较组间等位基因/氨基酸频率。
  • 使用计算机工具对关键HLA相关自身抗体亚组进行表位预测,评估抗原性、变应原性、毒性和与HLA等位基因的分子对接。

主要发现

  • HLA-C*07:01在IIM中具有保护作用(Pa=1.23×10^-2,OR=0.17,95%CI 0.06-0.41)。
  • HLA-A*33:03与DM相关(Pa=3.97×10^-3,OR=14.8,95%CI 4.38-68.07),DQB1*06:03与PM相关(Pa=2.40×10^-2,OR=7.24,95%CI 2.42-22.61)。
  • 抗Mi2亚组与A*33:03(Pa=2.82×10^-3,OR=19.73,95%CI 5.11-98.01)、DQA1*02:01(Pa=1.03×10^-2,OR=10.28,95%CI 2.33-53.75)和DQB1*03:03(Pa=1.98×10^-2,OR=8.99,95%CI 2.71-30.51)强相关。
  • 抗Ro52与B*08:01相关(Pa=2.94×10^-3,OR=11.67,95%CI 3.56-39.83)。
  • 精细定位发现DQA1第25位苯丙氨酸与抗Mi2a/b自身抗体阳性患者的风险等位基因DQA1*02:01相关;从49个预测的Mi-2肽段中,'YYKYILTR'、'QAFSRAHR'和'DYWEKLLR'与A*33:03稳定结合且无变应原性和毒性。

关键数值与推荐

  • HLA-C*07:01 protective in IIM: Pa=1.23×10^-2, OR=0.17, 95%CI 0.06-0.41.
  • HLA-A*33:03 with DM: Pa=3.97×10^-3, OR=14.8, 95%CI 4.38-68.07; DQB1*06:03 with PM: Pa=2.40×10^-2, OR=7.24, 95%CI 2.42-22.61.
  • Anti-Mi2 subgroup: A*33:03 Pa=2.82×10^-3, OR=19.73, 95%CI 5.11-98.01; DQA1*02:01 Pa=1.03×10^-2, OR=10.28, 95%CI 2.33-53.75; DQB1*03:03 Pa=1.98×10^-2, OR=8.99, 95%CI 2.71-30.51.
  • Anti-Ro52 with B*08:01: Pa=2.94×10^-3, OR=11.67, 95%CI 3.56-39.83.
  • Fine mapping: phenylalanine at position 25 of DQA1 linked to risk allele DQA1*02:01 in anti-Mi2a/b positive patients; from 49 predicted Mi-2 peptides, 'YYKYILTR', 'QAFSRAHR' and 'DYWEKLLR' bound stably to A*33:03 and were non-allergenic and non-toxic.

临床怎么用

  • 本研究识别的HLA associations和预测表位为理解IIM亚组(尤其抗Mi2亚组)的发病机制提供了线索,并提示抗原特异性免疫治疗的潜在靶点。
  • 抗Mi2相关的HLA/表位发现属探索性,临床应用于诊断或治疗前需在更大队列中确认并实验验证。

局限性

  • 抗Mi2相关的HLA/表位发现因统计功效有限属于探索性。
  • 需要在更大队列中确认并实验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify HLA associations with clinical and autoantibody-defined subgroups of idiopathic inflammatory myopathy (IIM) and predict potential immunogenic epitopes presented by subgroup-specific HLA alleles. METHODS: An observational case-control study was conducted including 147 biopsy-confirmed IIM patients and 114 ethnically matched healthy controls. Patients were classified into clinical and autoantibody-defined subgroups. High-resolution HLA genotyping was performed, and allele/amino acid frequencies were compared between the groups. Epitope prediction was carried out for key HLA-associated autoantibody subgroups using in silico tools assessing antigenicity, allergenicity, toxicity and molecular docking with HLA alleles. RESULTS: HLA-C*07:01 was protective in IIM (Pa = 1.23 × 10-2, OR = 0.17, 95% CI 0.06-0.41). Subgroup analysis showed associations of HLA-A*33:03 with DM (Pa = 3.97 × 10-3, OR = 14.8, 95% CI 4.38-68.07) and DQB1*06:03 with PM (Pa = 2.40 × 10-2, OR = 7.24, 95% CI 2.42-22.61). The anti-Mi2 subgroup showed strong associations with A*33:03 (Pa = 2.82 × 10-3, OR = 19.73, 95% CI 5.11-98.01), DQA1*02:01 (Pa = 1.03 × 10-2, OR = 10.28, 95% CI 2.33-53.75) and DQB1*03:03 (Pa = 1.98 × 10-2, OR = 8.99, 95% CI 2.71-30.51). Anti-Ro52 was associated with B*08:01 (Pa = 2.94 × 10-3, OR = 11.67, 95% CI 3.56-39.83). Fine mapping pinpointed phenylalanine at position 25 of DQA1 to the risk allele DQA1*02:01 in anti-Mi2a/b autoantibody positive patients. From 49 predicted Mi-2 peptides, 'YYKYILTR', 'QAFSRAHR' and 'DYWEKLLR' bound stably to A*33:03 and were non-allergenic and non-toxic. CONCLUSION: In the anti-Mi2 subgroup, we identified novel HLA alleles, amino acid variants and immunogenic epitopes, supporting a role for HLA-restricted antigen presentation in disease pathogenesis and indicating candidate targets for antigen-specific immunotherapy. However, the HLA/epitope findings related to anti-Mi2 are exploratory due to limited power, and require confirmation in larger cohorts together with experimental validation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Jassal B, Chopra G, Dhall A, et al. HLA variation analysis and autoantigen epitope prediction in idiopathic inflammatory myopathies. Rheumatology (Oxford). 2026. PMID: 41761579. doi:10.1093/rheumatology/keag049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。